Cargando…
14例结节性淋巴细胞为主型霍奇金淋巴瘤患者的临床病理特征与疗效分析
OBJECTIVE: To probe the clinical and pathological characteristics of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). METHODS: The pathologically confirmed 14 cases of NLPHL patients (since January 2001 to December 2012) were collected from Tianjin Medical University Cancer Hospital. The lab...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343041/ https://www.ncbi.nlm.nih.gov/pubmed/25641140 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.01.005 |
_version_ | 1783555678870175744 |
---|---|
collection | PubMed |
description | OBJECTIVE: To probe the clinical and pathological characteristics of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). METHODS: The pathologically confirmed 14 cases of NLPHL patients (since January 2001 to December 2012) were collected from Tianjin Medical University Cancer Hospital. The laboratory examinations' results, clinical manifestations, short-term and long-term outcomes of these cases were analyzed in this study. RESULTS: The immunohistochemistry of all cases showed CD20(+)/weak(+) and CD30(−), most of them CD15 (−). The morbidity of NLPHL during the same period of Hodgkin's lymphoma (HL) was around 6.3%. The median age was 38 (13–54) years old, 92.9% of the patients sought medical advice according to self-feeling of superficial lymph nodes. All patients' disease progressed slowly and the sizes of lymph nodes were within 3 cm. Of the 14 patients, 7 patients were treated with chemotherapy and 7 patients chemoradiotherapy. The treatment results showed CR+CRu rate as 85.7% and ORR 100.0%. The rates of 5-year event-free survival (EFS) and overall survival (OS) were 85.7% and 100.0% respectively. Short and long term efficacies between chemotherapy and chemoradiotherapy had no significant differences. Meanwhile, varieties chemotherapy regimens showed no significant effects on short-and long-term efficacies (P>0.05). CONCLUSION: The pathologically confirmed 14 cases of NLPHL had the classical and tumorous maxi cell, which showed CD20 (+)/weak (+) and CD30 (−), very few cases showed weak CD15 (+). The incidence of NLPHL was low. The majority of the NLPHL patients were middle-aged and youth. Moreover, the better short-and long-term outcomes over classical HL ones were observed regardless of patients' stage. |
format | Online Article Text |
id | pubmed-7343041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73430412020-07-16 14例结节性淋巴细胞为主型霍奇金淋巴瘤患者的临床病理特征与疗效分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To probe the clinical and pathological characteristics of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). METHODS: The pathologically confirmed 14 cases of NLPHL patients (since January 2001 to December 2012) were collected from Tianjin Medical University Cancer Hospital. The laboratory examinations' results, clinical manifestations, short-term and long-term outcomes of these cases were analyzed in this study. RESULTS: The immunohistochemistry of all cases showed CD20(+)/weak(+) and CD30(−), most of them CD15 (−). The morbidity of NLPHL during the same period of Hodgkin's lymphoma (HL) was around 6.3%. The median age was 38 (13–54) years old, 92.9% of the patients sought medical advice according to self-feeling of superficial lymph nodes. All patients' disease progressed slowly and the sizes of lymph nodes were within 3 cm. Of the 14 patients, 7 patients were treated with chemotherapy and 7 patients chemoradiotherapy. The treatment results showed CR+CRu rate as 85.7% and ORR 100.0%. The rates of 5-year event-free survival (EFS) and overall survival (OS) were 85.7% and 100.0% respectively. Short and long term efficacies between chemotherapy and chemoradiotherapy had no significant differences. Meanwhile, varieties chemotherapy regimens showed no significant effects on short-and long-term efficacies (P>0.05). CONCLUSION: The pathologically confirmed 14 cases of NLPHL had the classical and tumorous maxi cell, which showed CD20 (+)/weak (+) and CD30 (−), very few cases showed weak CD15 (+). The incidence of NLPHL was low. The majority of the NLPHL patients were middle-aged and youth. Moreover, the better short-and long-term outcomes over classical HL ones were observed regardless of patients' stage. Editorial office of Chinese Journal of Hematology 2015-01 /pmc/articles/PMC7343041/ /pubmed/25641140 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.01.005 Text en 2015年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 论著 14例结节性淋巴细胞为主型霍奇金淋巴瘤患者的临床病理特征与疗效分析 |
title | 14例结节性淋巴细胞为主型霍奇金淋巴瘤患者的临床病理特征与疗效分析 |
title_full | 14例结节性淋巴细胞为主型霍奇金淋巴瘤患者的临床病理特征与疗效分析 |
title_fullStr | 14例结节性淋巴细胞为主型霍奇金淋巴瘤患者的临床病理特征与疗效分析 |
title_full_unstemmed | 14例结节性淋巴细胞为主型霍奇金淋巴瘤患者的临床病理特征与疗效分析 |
title_short | 14例结节性淋巴细胞为主型霍奇金淋巴瘤患者的临床病理特征与疗效分析 |
title_sort | 14例结节性淋巴细胞为主型霍奇金淋巴瘤患者的临床病理特征与疗效分析 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343041/ https://www.ncbi.nlm.nih.gov/pubmed/25641140 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.01.005 |
work_keys_str_mv | AT 14lìjiéjiéxìnglínbāxìbāowèizhǔxínghuòqíjīnlínbāliúhuànzhědelínchuángbìnglǐtèzhēngyǔliáoxiàofēnxī AT 14lìjiéjiéxìnglínbāxìbāowèizhǔxínghuòqíjīnlínbāliúhuànzhědelínchuángbìnglǐtèzhēngyǔliáoxiàofēnxī AT 14lìjiéjiéxìnglínbāxìbāowèizhǔxínghuòqíjīnlínbāliúhuànzhědelínchuángbìnglǐtèzhēngyǔliáoxiàofēnxī AT 14lìjiéjiéxìnglínbāxìbāowèizhǔxínghuòqíjīnlínbāliúhuànzhědelínchuángbìnglǐtèzhēngyǔliáoxiàofēnxī AT 14lìjiéjiéxìnglínbāxìbāowèizhǔxínghuòqíjīnlínbāliúhuànzhědelínchuángbìnglǐtèzhēngyǔliáoxiàofēnxī AT 14lìjiéjiéxìnglínbāxìbāowèizhǔxínghuòqíjīnlínbāliúhuànzhědelínchuángbìnglǐtèzhēngyǔliáoxiàofēnxī AT 14lìjiéjiéxìnglínbāxìbāowèizhǔxínghuòqíjīnlínbāliúhuànzhědelínchuángbìnglǐtèzhēngyǔliáoxiàofēnxī AT 14lìjiéjiéxìnglínbāxìbāowèizhǔxínghuòqíjīnlínbāliúhuànzhědelínchuángbìnglǐtèzhēngyǔliáoxiàofēnxī AT 14lìjiéjiéxìnglínbāxìbāowèizhǔxínghuòqíjīnlínbāliúhuànzhědelínchuángbìnglǐtèzhēngyǔliáoxiàofēnxī AT 14lìjiéjiéxìnglínbāxìbāowèizhǔxínghuòqíjīnlínbāliúhuànzhědelínchuángbìnglǐtèzhēngyǔliáoxiàofēnxī AT 14lìjiéjiéxìnglínbāxìbāowèizhǔxínghuòqíjīnlínbāliúhuànzhědelínchuángbìnglǐtèzhēngyǔliáoxiàofēnxī AT 14lìjiéjiéxìnglínbāxìbāowèizhǔxínghuòqíjīnlínbāliúhuànzhědelínchuángbìnglǐtèzhēngyǔliáoxiàofēnxī |